APRI Score Calculator
Calculate the AST to Platelet Ratio Index (APRI) for liver fibrosis staging in hepatitis C and other chronic liver diseases.
Typical values: Male 40 U/L, Female 35 U/L (may vary by lab)
APRI Score Interpretation
| APRI Score | Fibrosis Stage | Clinical Significance |
|---|---|---|
| <0.5 | F0-F1 | No or minimal fibrosis (NPV 86% for excluding significant fibrosis) |
| 0.5-1.5 | Indeterminate | Uncertain, additional testing recommended |
| 1.5-2.0 | F2-F3 | Significant fibrosis likely |
| >2.0 | F3-F4 | Advanced fibrosis/cirrhosis (PPV 65% for cirrhosis) |
APRI Formula
APRI = ((AST / ULN) / Platelet count) × 100
Where:
- AST = Aspartate Aminotransferase level in U/L
- ULN = Upper Limit of Normal for AST (lab-specific, typically 40 U/L)
- Platelet count in ×10⁹/L (or ×10³/μL)
Clinical Information
What is the APRI Score?
The APRI (AST to Platelet Ratio Index) is a simple, non-invasive biomarker used to assess liver fibrosis severity. Originally developed and validated in patients with chronic hepatitis C, it has since been applied to other chronic liver diseases. APRI uses readily available laboratory values (AST and platelet count) to estimate the likelihood of significant fibrosis or cirrhosis.
Clinical Applications
- Primary screening for liver fibrosis in hepatitis C patients
- Monitoring disease progression in chronic liver disease
- Risk stratification before antiviral therapy
- Assessment in resource-limited settings where elastography unavailable
- Complementary use with other non-invasive markers (FIB-4, FibroTest)
- Evaluation in HIV/HCV co-infected patients
Performance Characteristics
For Significant Fibrosis (F2-F4):
- AUROC: 0.76-0.80
- Cutoff >0.7: Sensitivity 77%, Specificity 72%
- High NPV for excluding significant fibrosis at low scores
For Cirrhosis (F4):
- AUROC: 0.80-0.88
- Cutoff >1.0: Sensitivity 76%, Specificity 72%
- Cutoff >2.0: Sensitivity 48%, Specificity 91%
Advantages
- Simple calculation using routine laboratory tests
- Low cost and widely available
- No special equipment required
- Can be repeated frequently for monitoring
- Validated in multiple studies and populations
- Useful in resource-limited settings
Limitations
- Moderate accuracy compared to direct elastography or biopsy
- Large indeterminate zone requiring additional testing
- May be affected by thrombocytopenia from non-hepatic causes
- AST elevation from extrahepatic sources can confound results
- Less well validated in non-viral liver diseases
- Cannot distinguish between intermediate fibrosis stages
Clinical Recommendations by Score
APRI <0.5:
- Low probability of significant fibrosis
- May defer invasive testing
- Continue routine monitoring
- Reassess annually or if clinical change
APRI 0.5-1.5:
- Indeterminate risk, cannot rule in or out fibrosis
- Consider additional non-invasive tests (FIB-4, FibroScan)
- May need liver biopsy if treatment decisions depend on staging
- Specialist consultation recommended
APRI 1.5-2.0:
- Significant fibrosis likely present
- Refer to hepatology
- Consider confirmatory testing
- Initiate or optimize treatment
APRI >2.0:
- High probability of cirrhosis
- Urgent hepatology referral
- Screen for varices (esophagogastroduodenoscopy)
- Screen for hepatocellular carcinoma (ultrasound, AFP)
- Assess for complications of portal hypertension
- Initiate appropriate therapy
Frequently Asked Questions
Is APRI score accurate for all liver diseases?
APRI was originally developed and validated for chronic hepatitis C and shows best performance in this population. While it can be used in other chronic liver diseases (hepatitis B, NAFLD, alcohol-related liver disease), the accuracy may be lower. It should be interpreted with caution in non-viral liver diseases and ideally combined with other markers.
How does APRI compare to FIB-4?
Both APRI and FIB-4 are non-invasive fibrosis markers with similar accuracy. FIB-4 includes age and ALT in addition to AST and platelets, which may provide slightly better performance in some populations. Many clinicians calculate both scores and use them together for improved risk stratification. When scores are discordant, additional testing is usually warranted.
What should I do if my APRI score is in the indeterminate range?
An indeterminate APRI score (0.5-1.5) means the test cannot reliably exclude or confirm significant fibrosis. In this case, additional evaluation is needed. Options include calculating other non-invasive markers (FIB-4, Enhanced Liver Fibrosis score), performing transient elastography (FibroScan), or considering liver biopsy if management decisions depend on accurate staging.
Can medications affect my APRI score?
Yes, several factors can affect APRI accuracy. Medications or conditions that elevate AST (statins, muscle injury, hemolysis) can falsely increase the score. Conversely, conditions causing thrombocytopenia unrelated to liver disease (ITP, bone marrow disorders, medications) can also elevate APRI. Always consider clinical context when interpreting the score.
How often should APRI be monitored?
Monitoring frequency depends on the clinical scenario. In untreated chronic hepatitis C, annual assessment is typical. During antiviral treatment, more frequent monitoring (every 3-6 months) helps assess response. After successful treatment or in stable disease, annual or less frequent monitoring may be sufficient. Your hepatologist will determine the appropriate schedule.
What is the upper limit of normal (ULN) for AST?
The AST upper limit of normal varies by laboratory and may differ between genders. Typical values are 40 U/L for males and 35 U/L for females, but some labs use different ranges. Always use the ULN provided by your specific laboratory for accurate APRI calculation. This information is usually printed on your lab report.
Can APRI predict outcomes in liver disease?
Yes, APRI score has been shown to correlate with clinical outcomes. Higher APRI scores are associated with increased risk of hepatic decompensation, hepatocellular carcinoma, and liver-related mortality. Sequential APRI measurements can help track disease progression or improvement with treatment, providing valuable prognostic information.
Should I use APRI instead of liver biopsy?
APRI is a useful screening and monitoring tool but cannot completely replace liver biopsy. It works best for ruling out advanced fibrosis (high NPV at low scores) and identifying likely cirrhosis (high PPV at very high scores). For definitive staging, especially in the indeterminate range, or when other diagnostic information is needed, liver biopsy may still be necessary.